Compare
Two to four companies, one screen
The same numbers the feed and each dossier publish, lined up so you can weigh candidates against each other. Every figure is a public-filing estimate, identical for every subscriber, and the shaded cell in a row is simply the highest number in it — not a recommendation.
Add one more to line them up.
| Innovent Biologics (Suzhou) Co. Ltd. OncologyPhase II Remove | |
|---|---|
| Momentum0–100 | 39 |
| Runwayestimate, months | — |
| Stage | Phase II |
| Last raiseForm D, self-reported | No Form D on file |
| Lead investigator | — |
| What changed | Phase II trial registered: A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyApr 2025 · Trial registered |
| Full dossier → |
Momentum and runway are estimates derived from public federal filings, published identically to every subscriber. This is informational only and is not investment advice. How the numbers work